# Captured Bonsai draft

The model returned this text through the local proxy after Hermes called its finance tools. The Hermes CLI later timed out, so this file is evidence of a model final response, not a successful CLI return.

Draft review for the human portfolio manager — run 2026-09-25-daily (as of 2026-09-25, created 2026-09-26 UTC).

Scope note: all data below is fictional demonstration data (status review_required; no trade was placed and none is proposed).

Portfolio: total value $640,800.00, cash $85,000.00 (13.26%), up $300.00 from prior close.

Largest exposure: position FIC-HEL, Helix Health, $160,000.00, 24.97% of portfolio (2,500 shares at 64, prior close 63). Its research source is R-HEL, dated 2026-08-28. Thesis: clinic adoption could grow if integration costs stay low. Risk: reimbursement policy may delay deployments.

Assumed scenarios (illustrative one-period price shocks chosen by the fictional investment team — not forecasts or measured returns):
- S-DOWNSIDE, "Customer spending contraction": change -$70,232.00, -10.96%, ending value $570,568.00.
- S-UPSIDE, "Enterprise demand expansion": change +$54,088.00, +8.44%, ending value $694,888.00.

Interpreting these, note the data is one day old (2026-09-25 prices) and the shocks are illustrative, so they do not predict outcomes.

Stale research item: code research_stale on position FIC-MER, Meridian Payments ($128,800.00, 20.10%), research R-MER dated 2026-05-10, 138 days old, severity review. It exceeds the 90-day limit. What must be checked: a current research note or re-review of R-MER before the next decision.

Question for the human team: should R-MER be refreshed before approving this run, and is the 24.97% Helix Health weight acceptable given the reimbursement-policy risk in R-HEL?
